Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer
Tóm tắt
Background: Thyroglobulin is an excellent biological marker of persistent or recurrent thyroid cancer during long-term follow-up. Most studies investigated its diagnostic value but not its prognostic value over time. We aim to study the prognostic value of thyroglobulin levels early after total thyroidectomy, before iodine ablation. Methods: The study was based on the Rabin Medical Center registry of patients with non-medullary thyroid carcinoma. Data were collected on the clinical, laboratory, and outcome characteristics of 420 consecutive patients followed at our institution for whom early post-operative pre-ablation thyroglobulin values (baseline thyroglobulin) were available. Results: Patients were classified into 4 groups by baseline thyroglobulin level: 0–2, 2–10, 10–100, and >100 ng/ml. Higher levels were associated with a shift toward male gender (p=0.01), larger tumor size (p=0.02), and a more extensive disease (p<0.0001). They were also related to disease persistence and evidence of disease at last follow-up (p<0.0001). The 10 ng/ml cut-off level identified patients with persistent disease with a sensitivity and specificity of 73%, positive predictive value of 43%, and negative predictive value of 89%. On multivariate analysis, the following variables were predictive of persistent disease: baseline thyroglobulin level, male gender, lymph-node involvement, distant metastases, higher tumor invasiveness, and larger tumor size. However, the predictive power of baseline thyroglobulin level was relatively weak (odds ratio 1.002, 95% confidence interval 1.00–1.04). Conclusions: In patients with well-differentiated thyroid cancer, a post-thyroidectomy thyroglobulin level <10 ng/ml is associated with a low probability of having persistent disease and can be used combined with other disease characteristics for decisions regarding treatment and follow-up.
Tài liệu tham khảo
Schlumberger MJ, Filetti S, Hay ID. Non toxic diffuse and nodular goiter and thyroid neoplasia. In: Kronenberg HM, Melmed S, Polonsky HS, Larsen PR editors. Williams textbook of endocrinology. Philadelphia: WB Saunders. 2008, 420–45.
Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2006, 56: 106–30.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen BR, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19: 1167–214.
Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurments in the follow-up of differentiated thyroid carcinoma, a structured meta analysis. Clin Endocrinol (Oxf) 2004, 61: 61–74.
Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thryglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88: 1433–41.
Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007, 92: 82–7.
Rosario PW, Purisch S. Does a highly sensitive throglobulin (Tg) assay change the clinical management of low risk patients with thyroid cancer with Tg on T4<1 ng/ml determined by traditional assays?. Clin Endocrinol (Oxf) 2008, 68: 338–42.
Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay during thyroxine treatment in low risk differentiated thyroid cancer management. Comparison with recombinant human thyrotropinstmuliated assay and imaging procedures. Clin Chem Lab Med 2006, 44: 648–52.
Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007, 92: 2487–95.
Iervasi A, Iervasi G, Ferdeghini M, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2007, 67: 434–41.
Grunwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nuc Med 1996, 37: 1962–4.
Verkooijen RB, Rietbergen D, Smit JW, Romijn JA, Stokkel MP. A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow up. Eur J Endocrinol 2007, 156: 41–7.
Giovanella L, Ceriani L, Suriano S, Ghelfo A, Maffioli M. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastasis from differentiated thyroid carcinoma. Clin Endocrinol 2008, 69: 659–63.
Huang SH, Wang PW, Huang YE, et al. Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis. Thyroid 2006, 16: 1273–8.
Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med 2005, 43: 843–7.
Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005, 90: 1440–5.
Heemstra KE, Liu YY, Stokel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2007, 66: 58–64.
Lin JD, Huang MJ, Hsu BR-S, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol 2002, 80: 45–51.
AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag 2002.
Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004, 150: 105–12.